Hualan Biological Engineering Inc.
002007
Hisse Senetlerindeki Sıralama
#4385
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Hisse Fiyatı
$1.92
Piyasa Değeri
$3.50B
Değişim (1 gün)
-1.39%
Değişim (1 yıl)
-19.45%
Ülke
CN
Ticaret Hualan Biological Engineering Inc. (002007)
Kategori
Healthcare
Hualan Biological Engineering Inc. (002007) için kazanç
2026 itibarıyla kazanç TTM: 0
Hualan Biological Engineering Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Hualan Biological Engineering Inc. için kazanç geçmişi 2001 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2025 | $167.71M | -8.55% |
| 2024 | $183.39M | -37.52% |
| 2023 | $293.51M | 41.74% |
| 2022 | $207.07M | -22.04% |
| 2021 | $265.62M | -19.19% |
| 2020 | $328.71M | 42.15% |
| 2019 | $231.25M | 14.45% |
| 2018 | $202.06M | 42.35% |
| 2017 | $141.94M | 8.99% |
| 2016 | $130.23M | 22.12% |
| 2015 | $106.65M | 5.21% |
| 2014 | $101.36M | 9.59% |
| 2013 | $92.49M | 54.63% |
| 2012 | $59.81M | -18.03% |
| 2011 | $72.97M | -41.17% |
| 2010 | $124.03M | 8.15% |
| 2009 | $114.69M | 259.64% |
| 2008 | $31.89M | 81.62% |
| 2007 | $17.56M | 50.98% |
| 2006 | $11.63M | 57.73% |
| 2005 | $7.37M | 35.90% |
| 2004 | $5.43M | 7.53% |
| 2003 | $5.05M | 23.80% |
| 2002 | $4.08M | 86.85% |
| 2001 | $2.18M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $3.01B | - |
BE
|
|
| $1.95B | - |
NL
|
